UTAH MEDICAL PRODUCTS INCUTMDEarnings & Financial Report
Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...
UTMD Q4 FY2025 Key Financial Metrics
Revenue
$9.0M
Gross Profit
$5.3M
Operating Profit
$2.4M
Net Profit
$2.6M
Gross Margin
58.2%
Operating Margin
27.0%
Net Margin
28.4%
YoY Growth
-1.2%
EPS
$0.80
UTAH MEDICAL PRODUCTS INC Q4 FY2025 Financial Summary
UTAH MEDICAL PRODUCTS INC reported revenue of $9.0M (down 1.2% YoY) for Q4 FY2025, with a net profit of $2.6M (down 11.6% YoY) (28.4% margin). Cost of goods sold was $3.8M, operating expenses totaled $2.8M.
Key Financial Metrics
| Total Revenue | $9.0M |
|---|---|
| Net Profit | $2.6M |
| Gross Margin | 58.2% |
| Operating Margin | 27.0% |
| Report Period | Q4 FY2025 |
UTAH MEDICAL PRODUCTS INC Annual Revenue by Year
UTAH MEDICAL PRODUCTS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $38.5M).
UTAH MEDICAL PRODUCTS INC Quarterly Revenue & Net Profit History
UTAH MEDICAL PRODUCTS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $9.0M | -1.2% | $2.6M | 28.4% |
| Q3 FY2025 | $9.8M | -1.9% | $2.6M | 26.8% |
| Q2 FY2025 | $10.0M | -4.3% | $3.0M | 30.6% |
| Q1 FY2025 | $9.7M | -14.4% | $3.0M | 31.3% |
| Q4 FY2024 | $9.2M | -25.7% | $2.9M | 31.7% |
| Q3 FY2024 | $10.0M | -20.0% | $3.6M | 35.6% |
| Q2 FY2024 | $10.4M | -19.2% | $3.5M | 33.2% |
| Q1 FY2024 | $11.3M | -9.4% | $4.0M | 34.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.3M | $10.4M | $10.0M | $9.2M | $9.7M | $10.0M | $9.8M | $9.0M |
| YoY Growth | -9.4% | -19.2% | -20.0% | -25.7% | -14.4% | -4.3% | -1.9% | -1.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $135.4M | $130.0M | $129.7M | $122.5M | $122.5M | $120.8M | $122.0M | $122.5M |
| Liabilities | $7.7M | $6.0M | $5.5M | $5.1M | $5.5M | $3.3M | $3.7M | $3.3M |
| Equity | $127.7M | $124.1M | $124.2M | $117.4M | $117.0M | $117.5M | $118.3M | $119.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $5.3M | $2.8M | $3.9M | $2.9M | $4.5M | $2.9M | $3.9M | $3.5M |